1. Home
  2. IBCP vs ARVN Comparison

IBCP vs ARVN Comparison

Compare IBCP & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Independent Bank Corporation

IBCP

Independent Bank Corporation

HOLD

Current Price

$33.01

Market Cap

695.4M

Sector

Finance

ML Signal

HOLD

Logo Arvinas Inc.

ARVN

Arvinas Inc.

HOLD

Current Price

$10.82

Market Cap

658.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IBCP
ARVN
Founded
1864
2015
Country
United States
United States
Employees
270
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
695.4M
658.2M
IPO Year
2010
2018

Fundamental Metrics

Financial Performance
Metric
IBCP
ARVN
Price
$33.01
$10.82
Analyst Decision
Hold
Buy
Analyst Count
2
19
Target Price
$37.00
$15.05
AVG Volume (30 Days)
121.2K
651.5K
Earning Date
04-23-2026
05-04-2026
Dividend Yield
3.35%
N/A
EPS Growth
3.48
58.84
EPS
3.27
N/A
Revenue
$32,075,000.00
$262,600,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$8.98
N/A
P/E Ratio
$10.30
N/A
Revenue Growth
0.30
N/A
52 Week Low
$29.63
$5.90
52 Week High
$37.39
$14.22

Technical Indicators

Market Signals
Indicator
IBCP
ARVN
Relative Strength Index (RSI) 43.03 49.58
Support Level $31.55 $9.02
Resistance Level $33.47 $12.43
Average True Range (ATR) 0.93 0.51
MACD -0.08 0.04
Stochastic Oscillator 12.43 61.68

Price Performance

Historical Comparison
IBCP
ARVN

About IBCP Independent Bank Corporation

Independent Bank Corp. operates as a commercial bank. It offers a broad range of banking services to individuals and businesses, including checking and savings accounts, commercial lending, direct and indirect consumer financing, mortgage lending, and safe deposit box services. It also provides internet and mobile banking capabilities to its customers. The firm's principal markets are the rural and suburban communities across Lower Michigan. The firm generates the majority of its revenue from Interest and fees on loans.

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Share on Social Networks: